Compare GNPX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNPX | VVOS |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 9.7M |
| IPO Year | 2017 | 2020 |
| Metric | GNPX | VVOS |
|---|---|---|
| Price | $0.77 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | ★ 708.5K | 184.8K |
| Earning Date | 05-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,443,000.00 |
| Revenue This Year | N/A | $69.66 |
| Revenue Next Year | N/A | $48.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.14 | $0.58 |
| 52 Week High | $12.97 | $7.40 |
| Indicator | GNPX | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 25.43 | 29.38 |
| Support Level | $0.15 | N/A |
| Resistance Level | $2.12 | $1.50 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 8.39 | 9.00 |
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.